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Introduction
A diverse range of drug delivery systems has
been developed for animal welfare (The Merck
Veterinary manual, 2010). In veterinary practice
drug delivery strategies are complicated by the
species diversity, breeds treated, body size varia-
tions, different husbandry practices, seasonal influ-
ences, cost constraints, food and fiber drug
persistence, level of convenience etc.
The primary routes of drug administration uti-
lized in veterinary medicine include oral and par-
entral dosing (Riviere and Papich, 2001).
Transdermal drug delivery system/patches imply
topical drug application to achieve systemic phar-
macological effects (Kumar et al., 2010). Great
strides over the last decade have been made in
using topical ‘pour-on’ and ‘spot-on’ drug applica-
tions for transdermal delivery in veterinary practice
(e.g. application of fenthion, fipronil, ivermectin,
levamisole). Advantages of topical application of
veterinary pharmaceuticals include reduction in
first pass metabolism, non invasiveness, gastric
route avoidance, continuous inputs of drugs with
short half lives, elimination of pulsed entry into the
systemic circulation and improved owner compli-
ance (Roberts et al., 2002).
Factors affecting transdermal drug movement
Species differences in skin structure
Skin being the largest organ of the body performs
a myriad of biological functions. It is an efficient
barrier to prevent penetration, and thus systemic
absorption, of most hydrophilic and ionic com-
pounds. Significant species differences have an im-
pact on the design of transdermal patches. In fact
the differences exist among different body regions
within a species due to variations in thickness, hair
follicle density, structure and arrangement and the
cutaneous blood flow. Significant differences in
transdermal penetration have been observed owing
to marked species differences in skin structure.  In
humans, the rate of penetration for most non-ion-
ized compounds is scrotal >foresheed > axilla/scalp
> back/abdomen > palmar and planter. In veteri-
nary medicine the primary site used for transdermal
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patch delivery is the back because animals cannot
like, chew or scratch. However, in sick or debili-
tated patients lateral thorax or inguinal areas are
used. The percutaneous absorption of chemicals
across laboratory animals species, pigs, primates
and humans is mouse >> rats/rabbits >
humans/pigs and primates. Rats, mice and pigs are
often used as models to investigate transdermal
drug penetration in development of formulations
for human use. The extrapolation of these data to
humans is controversial due to marked species dif-
ferences in the transdermal penetration of a number
of drugs, with the pig emerging as the model of
choice to investigate potential topical formulations
for human use. Functions of the skin in domestic
animals (Cattle/Sheep/Goat) is affected by factors
such as surface temperature, sebum output, vari-
ability in skin thickness, seasonal variations, breed
differences, density of hair follicles, body weight,
age and sex (Pitsman and Rostas, 1981). The pen-
etration of levamisole with organic solvents is
higher through cattle skin than through human skin.
However, the reverse is true with aqueous solution.
The penetration through the appendages could be
due to emulsified sebum in the cattle skin.
Molecular penetration through the skin
Epidermal transport
The diffusivity of the drug through the skin, includ-
ing the SC, is limited by the binding of the drug to
keratinocytes, the viscosity of the intercellular en-
vironment and the tortuosity of the pathway
(Roberts et al., 2002). Transport via a transcellular
pathway is unlikely because it would require re-
peated partitioning of the solute between lipophilic
and hydrophilic compartments, including the al-
most impenetrable intracellular matrix of the ker-
atinocytes. All solutes are transported through a
lipid pathway with resistance to passage of
lipophilic solutes arising from the dermis and not
the keratinocytes. The permeability of very polar
solutes through the SC is almost constant, while
permeability for lipophilic solutes changes with the
degree of lipophilicity (Matsuzaki et al., 1993). The
intercellular pathway for polar solutes may be pre-
dominantly the aqueous regions surrounding polar
intercellular lipids. The ideal solutes for topical de-
livery include as non-ionic, reasonably lipophilic
and, particularly, of small molecular weight (Mag-
nusson et al., 2004).
Appendageal transport
In TDDS, the appendageal transport (through hair
follicles and sweat glands) is controversial due o
relatively sparse hair cover in animals (Pig) and
smaller contribution to the total surface area
(Roberts et al., 2002). As the hair follicle density
increases, the follicular route of drug penetration
becomes more significant (Hueber et al., 1994).
Molecular considerations
The ideal characteristics of pharmacological agents
for TDD include low molecular weight (6500 Da),
few atoms available for hydrogen bonding,
lipophilicity < 2.6 and a low melting point (Mag-
nusson et al., 2004).
Vehicle and formulations
Vehicles must be sufficiently soluble to contain the
active drug in an aesthetically acceptable form (i.e.,
no granules), and the drug must simultaneously be
sufficiently soluble in the SC lipids and be able to
diffuse through these intercellular lipids to reach
the site of intended action (Kaplun-Frischoff and
Touitou, 1997).
Integrity of the skin
The progressive loss of the SC greatly diminishes
the barrier function of skin. Extraction of intercel-
lular lipids with various solvents causes a reduction
in the barrier function of the SC (Monteiro-Riviere
et al., 2001). Delipidation of skin by acetone in-
creases transdermal penetration of salicylate (Ben-
feldt et al., 1999). Altering lipid content and
fluidity is one strategy to enhance transdermal per-
meability. Similarly, lipid composition that varies
with diseases of the epidermis dramatically affects
drug movement through the SC.
Mechanism of Drug Delivery
The principle mechanism for drug delivery in
TDDS is “a slow process of diffusion driven by the
gradient between the high concentration in the de-
livery system and the zero concentration prevailing
in the skin”. The drug permeation across the skin
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obeys Fick’s first law which states that the steady
state of drug flux across a membrane can be ex-
pressed as Flux (J) = DP / h (concentration gradi-
ent) (surface area), Where D is the diffusivity of
the drug in the intercellular lipids of the stratum
corneum, P is the partition coefficient for the drug
between stratum corneum and the dosing medium
on the skin surface, and h is the skin thickness or
actual path length through which the drug diffuses
across the diffusion barrier. The driving force for
this process is the concentration gradient that exists
between the applied dose and the blood-perfused
dermal environment. The term DP/h is often called
the permeability coefficient. Kinetically, this is
first-order rate constant that is the basis for the ab-
sorption rate constant (Ka) obtained in pharmaco-
kinetic analyses of transdermal drug delivery
studies. Among the species, the factors that may
alter drug flux include skin thickness, hair density
and thus interfollicular epidermal thickness, as well
as differential lipid composition. Factors like dif-
ferent rates of cutaneous blood flow, capacity of
mechanisms of first pass cutaneous biotransforma-
tion, occlusion, high relative humidity, tempera-
ture, and disease induced changes in the skin
structure or function, and/or abrasion, may also
alter the transdermal flux.
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Fig. 1. Structure of Transdermal Drug Delivery Systems
A (adhesive), B (reservoir), or C (Laminated matrix) – Adapted from: Riviere and Papich (2001)
Components of Transdermal Patch
Liner: 
It protects the patch during storage and should be
removed before its use.
Drug: 
Drug solution is in direct contact with release liner.
Adhesive: It serves to adhere the components of the
patch together along with adhering the patch to the
skin e.g. Acrylic, Polyisobutylene (PIB), and Sili-
cone. 
Membrane:
It controls the release of the drug from the reservoir
and multi-layer patches.
Backing: 
The film protects the patch from the outer environ-
ment.
Types of Transdermal Drug Delivery Systems
TDDSs are classified as passive and active deliv-
ery systems. The former one relies completely on
the principle of diffusion while the latter, though
based on the same principle, consists of different
penetration technologies ranging from electrical
current, iontophoresis, electroporation, micropo-
ration, laser ablation, mechanical arrays, radio fre-
quency, thermal/heat, and ultrasound, etc. Both
these types are horizontally classified as follows
(Kumar et al., 2010).
a) Single layer drug in adhesive: In this type the
adhesive layer surrounded by a temporary liner
and a backing contains the drug and not only
serves to adhere the various layers together but
is also responsible for the releasing the drug to
the skin.
b) Multi -layer drug in adhesive: This type is also
similar to the single layer but it contains an im-
mediate drug release layer besides the other
layer that allows controlled release of the drug.
This patch has a temporary liner-layer and a per-
manent backing.
c) Vapour patch: In this patch (commonly used for
releasing of essential oils in decongestion) the
role of adhesive layer not only serves to adhere
the various layers together but also serves as re-
lease vapour.
d) Reservoir system: In this system the drug reser-
voir is embedded between an impervious back-
ing layer and a rate controlling membrane. The
drug releases only through the rate controlling
membrane, which can be micro porous or non
porous. In the drug reservoir compartment, the
drug can be in the form of a solution, suspen-
sion, gel or dispersed in a solid polymer matrix.
Hypoallergenic adhesive polymer can be applied
as outer surface polymeric membrane which is
compatible with drug.
e) Matrix system: 
i. Drug-in-adhesive system: In this type the drug
reservoir is formed by dispersing the drug in an
adhesive polymer and then spreading the med-
icated adhesive polymer by solvent casting or
melting (in the case of hot-melt adhesives) on an
impervious backing layer. On top of the reser-
voir, unmediated adhesive polymer layers are
applied for protection purpose. 
ii. Matrix-dispersion system: In this type the drug
is dispersed homogenously in a hydrophilic or
lipophilic polymer matrix. This drug containing
polymer disk fixed on to an occlusive base plate
in a compartment fabricated from a drug imper-
meable backing layer. Instead of applying the
adhesive on the face of the drug reservoir, it is
spread along with the circumference to form a
strip of adhesive rim.
f) Micro-reservoir system: In this type the drug de-
livery system is a combination of reservoir and
matrix-dispersion system. The drug reservoir is
formed by first suspending the drug in an aque-
ous solution of water soluble polymer and then
dispersing the solution homogeneously in a
lipophilic polymer to form thousands of un-
reachable, microscopic spheres of drug reser-
voirs. This thermodynamically unstable
dispersion is stabilized quickly by immediately
cross-linking the polymer in situ by using cross
linking agents.
Transdermal penetration ennhancement
Chemical enhancers
Penetration enhancers partition into, and interact
with skin constituents (intercellular lipid fraction)
and induce a temporary and reversible decrease in
skin barrier properties (Magnusson et al., 2001).
Their interaction with some components of the skin
increases fluidity in the intercellular lipids, possibly
inducing swelling of keratinocytes and/or leaching
out of structural components, reducing the barrier
function of the SC (Hirvonen et al., 1994). They
may increase (100-fold) skin permeability to
macromolecules (1–10 kDa) including heparin,
luteinising hormone releasing hormone (LHRH)
and oligonucleotides, without inducing skin irrita-
tion (Karande et al., 2004). Early penetration en-
hancers (dimethyl-sulfoxide and dimethylform-
amide) tend to be disruptive keratolytic agents that
destroy the SC and are non-specific in their pene-
tration enhancement. These accelerate the penetra-
tion of drugs such as antibiotics, steroids and local
anaesthetics (Franz et al., 1995), but have practical
drawbacks like toxicity, irritancy and odour (Chat-
taraj and Walker, 1995). Newer penetration en-
hancers with fewer drawbacks include propylene
glycol (Bendas et al., 1995), alcohols and surfac-
tants.
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Physical enhancers 
Here electrically generated currents or energy
fields are utilized in enhancing the transdermal
penetration of larger polar molecules that may not
normally be suitable for topical application and re-
ducing the lag time of topically applied products
like local anaesthetics.
Ultrasound: 
Low frequency ultrasound (20KHz) enhance the
drug (Insulin, Erythropoitin, Interferon) penetration
through human and rabbit skin (1000- fold) by dis-
turbing the SC layers by cavitation (Mitragotri et
al., 1995).
Iontophoresis:
Here small electrical current (0.5 mA/cm2) applied
between two electrodes in contact with the skin
drives a charged molecule (neutral molecules also)
through the barrier (Banga et al., 1999). Its effi-
ciency depends on the polarity, valency and mobil-
ity of the drug molecule besides the electrical cycle
and formulation containing the drug (Naik et al.,
2000). Iontophoresis enhances the SC delivery of
proteins, and oligonucleotides (Oldenburg et al.,
1995), lidocaine and fentanyl (Gupta et al., 1998).
Electrical current induced irreversible damage to
the growing hair due to least resistance of the hair
follicle is its potential drawback. 
Electroporation: 
It involves the application of short (ms) electrical
pulses (100–1000 V/cm) to the skin (Prausnitz et
al., 1993) which creates transient aqueous pores
through the SC (Jadoul et al., 1999), permitting
drugs (Vaccines, Liposomes, and Microspheres) to
penetrate more readily (Prausnitz, 1999). Electro-
poration has been used to enhance the transport of
vaccines (Misra et al., 1999), liposomes (Badkar et
al., 1999) and microspheres. It has simplified
physostigmine delivery as therapeutic agent for
organophosphate poisoning (Rowland and Chilcott,
2000). Skin damage using electroporation is similar
to iontophoresis (Prausnitz, 1999).
Particle-mediated epidermal delivery (PMED):
Here particles of gold, coated with DNA or protein
are accelerated into the epidermis by a similar de-
vice used to deliver DNA and protein vaccines
(Chen et al., 2002), which make contact with the
dense network of epidermal antigen presenting
cells (APCs) resulting in antigen presentation to the
systemic immune system by the transfected APCs
(Dean et al., 2005). Local keratinocytes also be-
come transfected and then express and secrete anti-
gen which is picked up by resident APCs (Dean et
al., 2005). PMED has been successfully used in
veterinary medicine against Influenza A virus in
pigs (Macklin et al., 1998), bovine herpesvirus-1
in cattle and cancer immunotherapy in dogs using
cytokine DNA (Keller et al., 1996).
Other Enhancement Techniques (Kumar and
Philip, 2007)
Transfersomes: 
The device penetrates the skin barrier along the
skin moisture gradient. Transfersome carriers can
create a drug depot in the systemic circulation that
is having a high concentration of drug. Transfer-
somes contain a component that destabilizes the
lipid bilayers and thus leading to the deformable
vesicles.
Medicated Tattoos: 
Med-Tatoos are modification of temporary tattoos
which contain an active drug substance for trander-
mal delivery. This technique is useful in the admin-
istration of drug in patients who are not able to take
traditional dosage forms.
Skin Abrasion:
This involves direct removal or disruption of the
upper layers of the skin (By creating micro chan-
nels in the skin by eroding the impermeable outer
layers with sharp microscopic metal granules – Mi-
croscissuining) to provide better permeation of top-
ically applied drug substance.
Controlled Heat Aided Drug Delivery (CHADD)
System: 
CHADD system consists a small unit that is used
for heating purpose, placed on top of a conven-
tional patch device. An oxidation reaction occurs
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Delivery site for microneedle technology (a) Hol-
low microneedles with applied formulation (b)
Solid microneedles (Adapted from Bora et al.,
2008) 
within the unit which tends to form heat of limited
intensity and duration. It facilitates the transfer of
drug substance to the blood circulation by applying
heat to the skin that increases the temperature and
ultimately leads to increase in microcirculation and
permeability in blood vessel. 
Laser Radiation:
This involves the exposure of the skin to the laser
beam that results in the ablation of the stratum
cornea without damaging the epidermis which re-
mains in contact with it. This technique improves
the delivery of lipophilic and hydrophilic drugs.
Magnetophoresis: 
The effect of magnetic field on diffusion flux of
drug substance is enhanced with increasing applied
strength.
Microfabricated Microneedles: 
These are the devices which have features of both
the hypodermic needle and transdermal patch and
transport the drug effectively across the member-
ane. The systems consists of a drug reservoir and
some projections (microneedles) extending from
the reservoir, these helps in penetrating the stratum
cornea and epidermis to deliver the drug. Mi-
croneedles do not penetrate deep enough into the
skin to reach up to the nerve endings and thus there
is no pain sensation during the microneedles inser-
tion into the skin (Bora et al., 2008). There are a
number of delivery approaches that have been em-
ployed to use the microneedles for TDDS. These
include:
Poke with patch approach- Involves piercing into
the skin followed by application of the drug patch
at the site of treatment.
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Polymer Physical property
Poly urethanes Elasticity
Poly siloxanes or silicones Insulating ability
Poly methyl methacrylate Physical strength and transparency
Poly vinyl alcohol Hydrophilicity and strength
Poly ethylene Toughness and lack of swelling
Poly vinyl pyrrolidone Suspension capabilities
Coat and poke approach- Needles coated with the
drug are inserted into the skin and release of
medicament then occurs by dissolution.
Biodegradable microneedles- Involves encapsula-
tion of the drug within the biodegradable, poly-
meric microneedles, which are then inserted into
the skin.
Hollow microneedles- Involves injecting the drug
through the needle with a hollow bore.
Metered-Dose Transdermal Spray (MDTS): It is a
liquid preparation used topically which is made up
of a volatile cum non volatile vehicle consisting of
completely dissolved medicament. The MDTS has
the following potential advantages:
• It improves delivery potential without skin irri-
tation due to its non-occlusive nature
• Increased acceptability
• Dose flexibility
• Simple manufacture
Polymers in Transdermal Drug Delivery System
Controlled drug release in TDDS can be achieved
by embedding the drug onto a polymeric material
and then releasing it in a predesigned controlled
manner from the polymer into the systemic circu-
Table 1. Polymers in Transdermal Drug Delivery System
lation. Polymers can be used as adhesives, as back-
ing layer for the transdermal patch, or to create a
gel that would help embed the drug for its con-
trolled delivery. Every layer in the transdermal drug
delivery system requires properties specific for that
layer only, which governs the polymer selection.
1: Polymer matrix diffusion controlled drug deliv-
ery system:
It is developed by dispersing drug particles in car-
rier matrix (in a homogenous manner) that is rate
controlling e.g. NitroDur designed for consistent
transdermal infusion of nitroglycerine.
2: Microreservoir partitioned controlled drug de-
livery system:
It involves dispersion of micro particles of suspen-
sion of drug (aqueous in nature) in a polymer using
high energy dispersion e.g. Syncromate implant en-
gineered to deliver subdermal administration of
norgestomet (Bharadwaj et al., 2011).
The polymers that are currently used in the for-
mulation of the transdermal patches include
Poly(2-hydroxy ethyl methacrylate), Poly(N-vinyl
pyrrolidone), Poly(methyl methacrylate),
Poly(vinyl alcohol), Poly(acrylic acid), Polyacry-
lamide, Poly(ethylene-co-vinyl acetate), Poly(eth-
ylene glycol), Poly(methacrylic acid). 
Veterinary Medicine -Transdermal Drug Devel-
opment (Riviere and Papich, 2001)
There are a number of variables that may affect
transdermal patch design in veterinary medicine
which could modulate drug release from the patch,
penetration across the stratum corneum, and/or ab-
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Table 2. Veterinary Drugs Considered for Transdermal Therapy (Davidson, 2003).
sorption into the systemic circulation. These in-
clude: 
1.Reduced permeability through stratum corneum
resulting in a rate-limiting diffusion
2. Improper patch adhesion on animal skin and its
interaction with surface lipids
3. Different hair, sebaceous, and sweat gland den-
sity and structure.
4. Different pH on skin surface.
5. Differential depot formation in the stratum
corneum and/or dermis
6. Different skin and body temperatures
7. Anatomical skin differences, differing rates of
cutaneous blood flow and/or patterns of dermal
perfusion.
8. Species-specific cutaneous biotransformation
9. Wide range of body sizes both within and among
species (Patch area:Total body mass is important
variable).
10. Systemic clearance of the compound which de-
termines the steady-state concentrations
11. Formulation factors.
Experimental studies that need to be conducted
for the development of a transdermal patch for vet-
erinary species include.
1.Evaluation of the candidate drug in a validated
in vitro model to assess its ability to penetrate
skin
2. In vitro formulation studies to optimize drug flux
in a controlled environment.
3. Determination of intravenous pharmacokinetics
parameters to allow stimulation of blood concen-
trations achievable with the drug and comparing
it to drug concentrations required for efficacy.
4. In vivo absorption study to validate in vitro sys-
tem.
5. Formulation of the transdermal patch based on
above validated model systems.
6. Inter-site and inter-species drug delivery assess-
ment.
7. Assessment of patch performance under varied
environmental conditions and application tech-
niques.
Potentials and Limitations
The most obvious potential for development of
transdermal patches in veterinary medicine in the
ease of dosing small animals and species that resist
medication (cats). The best drug candidates would
be those that otherwise require intravenous infu-
sion, frequent administrations, or that have poor
oral systemic availability. Cats and dogs are ideally
suited for TDDS development while pigs, goats
and sheep are appropriate and cattle and horses are
only feasible for very potent drugs where minimal
exposure (hormones) is efficacious.
Drugs that will never be appropriate for TDDS in-
clude those that are/have too large, too charged, in-
sufficient lipid solubility, tendency to cause direct
skin irritation, too rapid clearance, first pass cuta-
neous biotransformation, requirement of high peak
or low trough blood profiles and insufficient po-
tency. The patches must be designed which are not
amenable to removal by scratching, biting or lick-
ing, and a permanent dye has to be incorporated in
patches designed for food producing animals which
could allow excision of the depot at slaughter.
Conclusion
The use of transdermal medications is a milestone
in veterinary practice as they can be life-saving
therapeutic agents for patients that cannot tolerate
the administration of traditional dosage forms. In
Veterinary Medicine, TDDS has a great potential,
being able to use for both hydrophobic and hy-
drophilic active substances into promising deliver-
able drug. It is a realistic practical application as
the next generation of drug delivery system. Care-
ful monitoring, communication, and documenta-
tion will increase the success of any transdermally
administered therapy. Regardless of the likelihood
of clinical success from using a transdermal med-
ication, the safety of the caregiver must be the high-
est priority.
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